Head to Head Comparison: Global Wholehealth Partners (OTCMKTS:GWHP) and Accuray (NASDAQ:ARAY)

Accuray (NASDAQ:ARAY) and Global Wholehealth Partners (OTCMKTS:GWHP) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Accuray and Global Wholehealth Partners, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accuray	1	2	0	0	1.67
Global Wholehealth Partners	0	0	0	0	0.00

Accuray presently has a consensus price target of $2.00, indicating a potential upside of 521.12%. Given Accuray’s stronger consensus rating and higher probable upside, equities analysts clearly believe Accuray is more favorable than Global Wholehealth Partners.

Earnings & Valuation

This table compares Accuray and Global Wholehealth Partners”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accuray	$458.51 million	0.08	-$1.59 million	($0.37)	-0.87
Global Wholehealth Partners	N/A	N/A	N/A	($0.05)	N/A

Global Wholehealth Partners has lower revenue, but higher earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Global Wholehealth Partners, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

64.1% of Accuray shares are held by institutional investors. 4.4% of Accuray shares are held by insiders. Comparatively, 10.3% of Global Wholehealth Partners shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Accuray and Global Wholehealth Partners’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Accuray	-10.76%	-79.43%	-10.38%
Global Wholehealth Partners	N/A	N/A	N/A

Summary

Global Wholehealth Partners beats Accuray on 5 of the 9 factors compared between the two stocks.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

About Global Wholehealth Partners

Global WholeHealth Partners Corporation develops and markets various in-vitro diagnostic (IVD) test kits in the United States. The company offers approximately 125 diagnostic tests kits for over-the-counter or consumer-use, as well as for point-of-care, which includes hospitals, physicians' offices, and medical clinics. It provides tests for various diseases, such as Ebola, zika, dengue, malaria, influenza, tuberculosis, coronaviruses, yellow fever, and other epidemic and vector-borne diseases. The company was incorporated in 2013 and is based in Newport Beach, California.